Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.32 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.32 |
| ▸ | TUBB | P07437 | 2/20 | 0.32 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.32 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.32 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.32 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.32 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.32 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.32 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4133743 | 0.80 | GRIN2D (0.41) | SMN1; SMN2TUBB1TUBB4ATUBBTUBA3C | |
| SCHEMBL4125891 | 0.78 | ALDH1A1 (0.50) | RAB9ASMN1; SMN2HSD17B10ALDH1A1MCL1 | |
| SCHEMBL4802602 | 0.78 | MAPT (0.42) | NPC1USP2RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL4133431 | 0.78 | GAA (0.38) | NPC1USP2RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL4189369 | 0.70 | USP2 (0.38) | TRPA1APPNPC1USP2RAB9A | |
| SCHEMBL4129613 | 0.69 | MAPT (0.38) | RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL357217 | 0.69 | APP (0.62) | TRPA1APPTUBB1TUBB4ATUBB | |
| SCHEMBL4135402 | 0.69 | POLB (0.33) | — | |
| SCHEMBL4144143 | 0.68 | ALDH3A1 (0.47) | SMN1; SMN2TUBB1TUBB4ATUBBTUBA3C | |
| SCHEMBL17008455 | 0.64 | TAS1R3 (0.42) | ALDH1A1TDP1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | VAN POELJE PAUL D | 2009-08-06 | — | — | US | disclosed |
| US-7563774-B2 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | METABASIS THERAPEUTICS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| EP-1372660-A2 | A COMBINATION OF FBPASE INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030073728-A1 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | METABASIS THERAPEUTICS, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2002003978-A2 | A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073728-A1 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | FBP1, ALDOA, G6PC1 | TRPA1 4873/4885APP 4704/4885HDAC2 1479/4885 |
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | FBP1, ALDOA, G6PC1 | TRPA1 4873/4885APP 4704/4885HDAC2 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.